Clinical significance of non-culprit plaque regression following acute coronary syndrome: A serial intravascular ultrasound study.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
Aug 2019
Historique:
received: 05 11 2018
revised: 15 12 2018
accepted: 30 12 2018
pubmed: 10 2 2019
medline: 26 6 2020
entrez: 10 2 2019
Statut: ppublish

Résumé

The use of serial intravascular ultrasound (IVUS) for coronary atherosclerosis has offered valuable insight into plaque regression (PR) or progression. However, the beneficial effects of PR on the long-term clinical outcomes in patients with acute coronary syndrome (ACS) remain unclear. We aimed to evaluate the impact of coronary plaque change in patients following primary percutaneous coronary intervention. We retrospectively analyzed data from 4 prospective clinical trials involving 173 patients with ACS who underwent serial IVUS of non-culprit lesions on statin treatment at baseline and at 6 or 8 months of follow-up. The relationship of the IVUS findings with the change in percent atheroma volume (PAV), on-treatment low-density lipoprotein cholesterol (LDL-C), and major adverse cardiac and cerebrovascular events (MACCE) were investigated. In our serial IVUS analysis, baseline plaque volume and PAV were 79.6mm Achievement of both PR and sufficient lowering of the LDL-C was clinically important in post-ACS management.

Sections du résumé

BACKGROUND BACKGROUND
The use of serial intravascular ultrasound (IVUS) for coronary atherosclerosis has offered valuable insight into plaque regression (PR) or progression. However, the beneficial effects of PR on the long-term clinical outcomes in patients with acute coronary syndrome (ACS) remain unclear. We aimed to evaluate the impact of coronary plaque change in patients following primary percutaneous coronary intervention.
METHODS METHODS
We retrospectively analyzed data from 4 prospective clinical trials involving 173 patients with ACS who underwent serial IVUS of non-culprit lesions on statin treatment at baseline and at 6 or 8 months of follow-up. The relationship of the IVUS findings with the change in percent atheroma volume (PAV), on-treatment low-density lipoprotein cholesterol (LDL-C), and major adverse cardiac and cerebrovascular events (MACCE) were investigated.
RESULTS RESULTS
In our serial IVUS analysis, baseline plaque volume and PAV were 79.6mm
CONCLUSIONS CONCLUSIONS
Achievement of both PR and sufficient lowering of the LDL-C was clinically important in post-ACS management.

Identifiants

pubmed: 30737184
pii: S0914-5087(19)30011-5
doi: 10.1016/j.jjcc.2018.12.023
pii:
doi:

Substances chimiques

Cholesterol, LDL 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102-108

Informations de copyright

Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Auteurs

Hirohisa Endo (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Tomotaka Dohi (T)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan. Electronic address: tdohi@juntendo.ac.jp.

Katsumi Miyauchi (K)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Shoichi Kuramitsu (S)

Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan.

Yoshiteru Kato (Y)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Iwao Okai (I)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Miho Yokoyama (M)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Takayuki Yokoyama (T)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Kenji Ando (K)

Department of Cardiology, Kokura Memorial Hospital, Kitakyusyu, Japan.

Shinya Okazaki (S)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Kazunori Shimada (K)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Satoru Suwa (S)

Department of Cardiovascular Medicine, Juntendo University Shizuoka Hospital, Shizuoka, Japan.

Hiroyuki Daida (H)

Department of Cardiovascular Medicine, Juntendo University Graduate School of Medicine, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH